Topspin: Codagenix Raises $20M in Series B Funding

Codagenix, Inc., a Farmngdale, N.Y.-based clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, closed a $20m Series B funding round. The round was led by Adjuvant Capital, with participation from Euclidean Capital and Topspin Partners. The company intends to use the funds for the further clinical development of its live attenuated RSV vaccine [...]The post Codagenix Raises $20M in Series B Funding appeared first on FinSMEs.